Abstract
Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Niederman MS, Craven DE. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C, Canadian Critical Trials Group. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med. 1999;159:1249–1256.
Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122:2115–2121.
Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pnemonia. Respir Care. 2007;52:866–884.
Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis. 2009;22:154–158.
Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clinical Infectious Diseases. 2010;51(S1):S59–S66.
Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J. 2002;20:1483–1489.
Dallas J, Skrpky L, Abebe N, Boyle WA III, Kollef MH. Ventilator-associated tracheobronchitis (VAT) in a mixed surgical and medical ICU population. Chest. 2011;139:513–518. Epub.
A’Court CH, Garrard CS, Crook D, et al. Microbiologic lung surveillance in mechanically ventilated patients, using non-directed bronchial lavage and quantitative culture. Q J Med. 1993;86:635–648.
Nseir S, Ader F, Marquette CH. Nosocomial tracheobronchitis. Curr Opin Infect Dis. 2009;22:148–153.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–332.
Malacarne P, Langer M, Nascimben E, et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9493 patients from 71 Italian intensive care units. Crit Care Med. 2008;36:1105–1113.
Kampf G, Wischnewski N, Schulgen G, et al. Prevalence and risk factors for nosocomial lower respiratory tract infections in German hospitals. J Clin Epidemiol. 1998;51:495–502.
Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med. 2010;104:325–336.
Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med. 2001;29(suppl. 4):N64–N68.
Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemotherap. 2004;48:4606–4610.
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clinical Infectious Diseases. 2006;42:389–391. Epub.
Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest. 2000;117:1434–1442.
Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007;167:1393–1399.
Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest. 2005;127:589–597.
Depuydt P, Benoidt D, Vogelaers D, et al. Systemic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Intensive Care Medicine. 2008;34:675–682.
Yang KZH, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother. 2009;43:28–35.
Hayon J, Figliolini C, Combes A, et al. Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:41–46.
Rouby JJ, Martin De Lassale E, Poete P, et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis. 1992;146:1059–1066.
Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrobial Chemotherap. 1992;30:249–260.
Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–1095.
Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008;36:2008–2013.
Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003;168:1205–1209.
Weibel ER, Gil J. Structure-function relationships at the alveolar level. In West JB, ed. Bioengineering aspects of the lung. New York: Marcel Dekker, 1977.
Niederman MS. Principles of antibiotic use and the selection of empiric therapy for pneumonia. In Fishman’s Pulmonary Diseases and Disorders. Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM, eds. McGraw Hill, New York, 3rd ed; 1998. Chap 122; pp 1939–1949.
Stachelin LA. Structure and function of intercellular junctions. Int Rev Cytol. 1974;39:191–283.
Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemotherap. 1992;36:1171–1175.
Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infectious Diseases. 1983;148:1069–1076.
Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985;132:761–765.
Valcke Y, Pauwels R, Van der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J. 1990;3:715–722.
McCullagh A, Rosenthal M, Wanner A, Hurtado A, Padley S, Bush A. The bronchial circulation — worth a closer look. Pediatr Pulmonol. 2010;45:1–13.
Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987;136:1445–1449.
Bergogne-Bérézin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection. 1987;15:288–294.
LeConte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis. 1993;147:1279–1282.
Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv. 2008;21:45–60.
Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically-ventilated patients. Clin Chest Med. 2008;29:277–296.
O’Doherty MJ, Thomas SH, Page CJ, et al. Delivery of a nebulized aerosol to a lung model during mechanical ventilation. Effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis. 1992;146:383–388.
O’Riordan TG, Greco MJ, Perry RJ, et al. Nebulizer function during mechanical ventilation. Am Rev Respir Dis. 1992;145:1117–1122.
O’Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am J Respir Crit Care Med. 1994;149:214–219.
Palmer LB. Aerosolized antibiotics in critically ill ventilated patients. Curr Opin Crit Care. 2009;15:413–418.
Palmer LB, Smaldone GC, Simon SR, O’Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med. 1998;26:31–39.
Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47:1406–1416; discussion 1416–1418.
Pedersen KM, Handlos VN, Heslet L, Kristensen HG. Factors influencing the in vitro deposition of tobramycin aerosol: a comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J Aerosol Med. 2006;19:175–183.
Ehrmann S, Mercier E, Vecellio L, et al. Pharmacokinetics of high-dose nebulized amikacin in mechanically-ventilated healthy subjects. Intensive Care Medicine. 2008;34:755–762.
Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically-ventilated subjects. Expert Rev Med Devices. 2008;5:9–18.
Luyt CE, Clavel M, Guntupalli K, et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Critical Care. 2009;13;R200. Epub.
Zarilli GM, Monteforte M, Baram D, et al. Systemic versus aerosolized delivery of vancomycin for MRSA: concentrations in lungs and serum [abstract]. Am J Respir Crit Care Med. 2008;177:A286.
Geller DE, Flume P, Griffith DC. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemotherap. 2011;55:2636–2640.
King P, Lomovskaya O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemotherap. 2010;54:143–148.
King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis. 2010;66:181–186.
Inglis TJ, Millar MR, Jones JG, Robinson DA. Tracheal tube biofilm as a source of bacterial colonization of the lung. J Clin Microbiol. 1989;27:2014–2018.
Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002;347:1110–1111.
Shah C, Kollef MH. Endotracheal tube intraluminal volume loss among mechanically ventilated patients. Crit Care Med. 2004;32:120–125.
Adair CG, Gorman SP, Feron BM, et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Medicine. 1999;25:1072–1076.
Gorman SP, McGovern JG, Woolfson AD, Adair CG, Jones DS. The concomitant development of poly(vinyl chloride)-related biofilm and antimicrobial resistance in relation to ventilator-associated pneumonia. Biomaterials 2001;22:2741–2747.
Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K. Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis. 2002;57:84–87.
Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003;426:306–310.
Favre-Bonte S, Chamot E, Kohler T, Romand JA, van Delden C. Autoinducer production and quorum-sensing dependent phenotypes of Pseudomonas aeruginosa vary according to isolation site during colonization of intubated patients. BMC Microbiol. 2007;7:33.
Greenberg EP. Bacterial communication: tiny teamwork. Nature. 2003;424:134.
Le Berre R, Nguyen S, Nowak E, et al. Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2008;14:337–43. Epub.
Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171:1209–1223. Epub.
Latifi A, Foglino M, Tanaka K, Williams P, Lazdunski A. A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. Mol Microbiol. 1996;21:1137–1146.
Dénervaud V, TuQuoc P, Blanc D, et al. Characterization of cell-to-cell signaling-deficient Pseudomonas aeruginosa strains colonizing intubated patients. J Clin Microbiol. 2004;42:554–562.
Kohler T, Guanella R, Carlet J, van Delden C. Quorum sensing dependent virulence during Pseudomonas aeruginosa colonization and pneumonia in mechanically ventilated patients. Thorax. 2010;65:703–710.
Njoroge J, Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol Med. 2009;1:201–210.
Zhuo H, Yang K, Lynch SV, et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med. 2008;36:2495–2503.
Matsushima A, Tasaki O, Shimizu K, et al. Preemptive antibiotic treatment based on Gram staining reduced the incidence of ARDS in mechanically ventilated patients. J Trauma. 2008;65:309–315.
Marr AK, Overhage J, Bains M. The Lon protease of Pseudomonas aeruginosa is induced by aminoglycosides and is involved in biofilm formation and motility. Microbiology. 2007;153:474–482.
Adair CG, Gorman SP, Byers LM, et al. Eradication of endotracheal biofilm by nebulized gentamicin. Intensive Care Medicine. 2002;28:426–431.
Kollef MH, Afessa B, Anzueto A et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA. 2008;300;805–813.
Raad II, Mohamed JA, Reitzel RA, et al. The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials. 2011;32:2689–2694.
Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Pharmacotherapy. 2010;30:562–584.
Geller DE, Flume PA, Staab D, et al. Levofloxacin Inhalation Solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183:1510–1516. Epub.
Torres A, Valencia M. Does ventilator-associated tracheobronchitis need antibiotic treatment? Critical Care. 2005;9:255–256. Epub.
Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med. 2000;162:328–330.
Ahmed QA, Niederman MS. Respiratory infection in the chronically critically ill patient. Ventilator-associated pneumonia and tracheobronchitis. Clin Chest Med. 2001;22:71–85.
Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007;58:235–240.
Nseir S, DiPompeo C, Soubrier S, et al. Outcomes of ventilated COPD patients with nosocomial tracheobronchitis: a case control study. Infection. 2004;32:210–216.
Nseir S, DiPompeo C, Soubrier S, et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case control study. Critical Care. 2005;9:R238–R245.
Nsier S, Favory R, Josefowicz E, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study. Critical Care. 2008;12:R62.
Cunha BA. Aerosolized antibiotics are not a good idea-don’t go with the flow: Premum Non Nocere! Crit Care Med. 2009;37:799–800; author reply 800–801.
Rello J. Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Critical Care. 2005;9:259–265.
Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome of hospitalized patients. Clinical Infectious Diseases. 2000;31;S131–S138.
Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146–155.
Cosgrove SE, Kaye KS, Elipoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162:185–190.
Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210–1218.
Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest. 2005;128:2778–2787.
Schlueter M, James C, Dominguez A, et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection. 2010;38:357–362.
Masterton RG. Antibiotic de-escalation. Crit Care Clin. 2011;27:149–162.
Klepser ME. Role of nebulized antibiotics for the treatment of respiratory infections. Curr Opin Infect Dis. 2004;17:109–112.
Lesho E. Role of inhaled antibacterials in hospital acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther. 2005;3:445–451.
Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: A critical appraisal of their use. Expert Opin Drug Delivery. 2006;3:71–86.
Czosnowski QA, Wood GC, Magnotti LJ, et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy. 2009;29:1054–1060.
Ghannam DE, Rodriguez DH, Raad II, Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009;28:253–259.
Niederman MS, Chastre J, Corkery K, et al. Inhaled amikacin reduces IV antibiotic use in intubated mechanically ventilated patients (abstract). Am J Respir Crit Care Med. 2007;175:A326.
Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia. J Antimicrob Chemotherap. 2007;60:1216–1226.
Lu Q, Yang J, Liu Z, et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;184:106–115. Epub 2011.
Mohr AM, Sifri ZC, Horng HS, et al. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg Infect (Larchmt). 2007;8:349–357.
Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94:281–288.
Falagas ME, Kasiakou SK, Tsiordas S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. CM &R. 2006;4:138–146.
Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Infectious Diseases. 1999;28:1008–1011.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical Infectious Diseases. 2003;36:1111–1118.
Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of sepsis from multi resistant gram-negative bacilli in critically ill patients. Critical Care. 2003;37:e154–e160.
Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Critical Care. 2003;7:R78–R83.
Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemotherap. 2005;49:3136–3146.
Montero M, Horcajada JP, Sorli L, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009;37:461–465.
Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infectious Diseases. 2009;9:26.
Reina R, Estenssoro E, Saenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections. Intensive Care Medicine. 2005;31:1058–1065.
Kallel H, Bahloul M, Hergafi L, et al. Colistin as salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. International Journal of Antimicrobial Agents. 2006;28:366–369.
Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Sriraj Hospital, Bangkok, Thailand. Int Journal of Infectious Diseases. 2007;11:402–406.
Michalapoulos A, Kastakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care. 2005;9:R53–R59.
Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clinical Infectious Diseases. 2005;41:754–757.
Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005;62:39–47.
Mataouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect. 2006;53:274–278.
Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med. 2008;102:407–412.
Falagas ME, Siempos II, Rafailidis PI, et al. Inhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: a case series. Respir Med. 2009;103:707–713.
Michalopoulos A, Metaxas E, Falagas M. Aerosol delivery of antimicrobial Agents during mechanical ventilation: current practice and perspectives. Current Drug Delivery. 2011;8:208–212.
Singh N, Rogers P, Atwood CW, et al. Short course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505–511.
Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–2598.
Luyt CE, Eldon MA, Stass H, Gribben D, Corkery K, Chastre J. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv. 2011;24.
Stass H, Corkery K, Gribben D, Eldon MA. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease. J Aerosol Med Pulm Drug Deliv. 2011;24.
Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clinical Infectious Diseases. 2006;43:S89–S94.
McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357:2310–2311.
Feeley TW, Du Moulin GC, Hedley-Whyte J et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975, 293:471–475.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Abu-Salah, T., Dhand, R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an Update. Adv Therapy 28, 728–747 (2011). https://doi.org/10.1007/s12325-011-0051-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0051-z